Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Post-operative radioactive iodine administration in patients with low-risk thyroid cancer

Radioactive iodine (RAI) treatment is used in patients with thyroid cancer to treat disease and to eradicate normal thyroid remnants. Routine post-operative administration of RAI is no longer indicated in patients with low risk thyroid cancer and might instead be used selectively in patients with a post-operative high serum level of thyroglobulin.

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. Mazzaferri, E. L. & Jhiang, S. M. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am. J. Med. 97, 418–428 (1994).

    CAS  Article  Google Scholar 

  2. Pasqual, E. et al. Trends in the management of localized papillary thyroid carcinoma in the united states (2000–2018). Thyroid 32, 397–410 (2022).

    Article  Google Scholar 

  3. Mallick, U. et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N. Engl. J. Med. 366, 1674–1685 (2012).

    CAS  Article  Google Scholar 

  4. Schlumberger, M. et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N. Engl. J. Med. 366, 1663–1673 (2012).

    CAS  Article  Google Scholar 

  5. Schlumberger, M. et al. Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial. Lancet Diabetes Endocrinol. 6, 618–626 (2018).

    Article  Google Scholar 

  6. Dehbi, H. M. et al. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial. Lancet Diabetes Endocrinol. 7, 44–51 (2019).

    CAS  Article  Google Scholar 

  7. Lamartina, L., Durante, C., Filetti, S. & Cooper, D. S. Low-risk differentiated thyroid cancer and radioiodine remnant ablation: a systematic review of the literature. J. Clin. Endocrinol. Metab. 100, 1748–1761 (2015).

    CAS  Article  Google Scholar 

  8. Chou, R. et al. Serum thyroglobulin measurement following surgery without radioactive iodine for differentiated thyroid cancer: a systematic review. Thyroid (2022).

    Article  PubMed  Google Scholar 

  9. Nascimento, C. et al. Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level. Endocr. Relat. Cancer 18, R29–R40 (2011).

    CAS  PubMed  Google Scholar 

  10. Leboulleux, S. et al. Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer. N. Engl. J. Med. 386, 923–932 (2022).

    CAS  Article  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding authors

Correspondence to Sophie Leboulleux, Isabelle Borget or Martin Schlumberger.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Related links

Pathological tumour-node-metastasis:

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Leboulleux, S., Borget, I. & Schlumberger, M. Post-operative radioactive iodine administration in patients with low-risk thyroid cancer. Nat Rev Endocrinol (2022).

Download citation

  • Published:

  • DOI:


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing